ClinicalTrials.gg
TerminatedNCT04019002Updated Oct 27, 2026Results posted

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

A Phase 1 interventional study of Hyperpolarized Pyruvate (13C) and Magnetic Resonance Spectroscopic Imaging (MRSI) in Glioblastoma, Recurrent Glioblastoma and Glioblastoma Multiforme, sponsored by Susan Chang. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Susan Chang · Phase 1, Interventional, and Diagnostic

How we know

Why this study was terminated
Slow Accrual
Updated Oct 27, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
835th of 1,156
17 · median 33
Started
2019
with 48 others
Phase 1
482 of 1,303
70 open now
Registered
931st of 1,303
by date

Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 835th largest by enrollment of the 1,156 interventional ones that give a count, is one of 49 that started in 2019, is one of 482 in phase 1, and was the 931st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,303 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future.

If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized pyruvate 13C, to obtain dynamic metabolic imaging.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluation safety of hyperpolarized (HP) pyruvate (13C) injection for use in imaging lesions in participants with glioblastoma (GBM).

II. To evaluate metabolic changes in tumors and normal-appearing brain tissue in response to standard therapy.

EXPLORATORY OBJECTIVES:

I. To evaluate changes in 13C parameters from baseline to the post-RT scan compared in the normal appearing brain, enhancing lesion, non-enhancing lesion and the choline-to-N -acetyl aspartate (NAA) index (CNI) lesion.

II. To evaluate 13C metabolic parameters from the recurrent lesions compared to those in the regions of treatment related effects.

III. To evaluate 13C and 1H metabolic parameters to determine the association to time to progression and overall survival.

OUTLINE:

Participants are assigned to 3 cohorts based on disease status and non-investigational treatment plan. All participants enrolled in the study will receive at least 1 hyperpolarized pyruvate (13C) injection.

COHORT 1: Participants with newly diagnosed glioblastoma who will undergo standard of treatment with radiotherapy and temozolomide (TMZ). Magnetic resonance spectroscopic imaging (MRSI) imaging will occur at 2 time points: Before receiving non-investigational treatment with radiation and chemotherapy, and at the first post-radiation follow-up scan. Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as a standard MR.

COHORT 2: Participants with recurrent, suspected GBM who will receive non-investigational surgical resection. MRSI imaging with hyperpolarized 13C pyruvate injection will occur at a single time point before surgery.

COHORT 3: Participants with recurrent suspected GBM who will undergo non-investigational standard treatment will have three MR examination time points. Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as standard MR. The MR examinations will occur prior to initiating therapy (baseline), at approximately 7-14 days after initiation of therapy, and 6-8 weeks after the initiation of therapy.

Participants will be follow-up for up to 2 months after completion of non-investigational treatment, and for 7 days after final injection of hyperpolarized 13C.

03

Conditions studied

  • Glioblastoma
  • Recurrent Glioblastoma
  • Glioblastoma Multiforme

Browse trials for

Keywords

  • Imaging Study
  • Magnetic Resonance Spectroscopic Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: proven newly diagnosed glioblastoma multiforme (GBM) who will undergo standard of treatment with radiation therapy (RT) and temozolomide (TMZ).
  • Cohort 2: Histologically proven recurrent suspected GBM who will receive surgical resection for the recurrence.
  • Cohort 3: Histologically proven recurrent suspected GBM who will undergo standard treatment for the recurrence.
  • Patients must be >/= 18 years old and with a > 16 weeks.
  • Patients must have a performance status of ≥ 70.
  • Patients must have adequate renal function: creatinine \< 1.5 mg/dL before imaging. These tests must be performed within 60 days prior to Hyperpolarized Imaging scan.
  • Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate the imaging examination or any disease that will obscure toxicity or dangerously alter response to the imaging agent.
  • Patients must not have (NYHA) Grade II or greater congestive heart failure
  • Patients must not have a history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
  • This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No exclusion to this study will be based on race.
  • Patients must sign an indicating that they are aware of the nature of this study. Patients must sign an authorization for the release of their protected health information.
  • Patients may not be known to be (HIV)-positive. HIV testing is not required for study participation.
  • Patients must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years.
  • Patients must not be pregnant or breast feeding. Women of are required to obtain a negative pregnancy test within 14 days of Hyperpolarized Imaging scan. Effective (men and women) must be used in subjects of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  • Subjects must be excluded from participating in this study if they are not able to comply with study and/or follow-up procedures.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Cohort 1: Newly Diagnosed Glioblastoma

    This arm is for participants with histologically proven newly diagnosed glioblastoma who will undergo non-investigational treatment with radiation therapy (RT) and temozolomide (TMZ). Participants will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (4-8 weeks later).

    Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)

  • Experimental
    Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection

    This arm is for participants with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence. Participants will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery.

    Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)

  • Experimental
    Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment

    This arm is for participants with histologically proven recurrent suspected who will undergo standard treatment for the recurrence. Participants will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment.

    Drug: Hyperpolarized Pyruvate (13C) · Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (AEs)

    Participants will be monitored for the occurrence of treatment-emergent AEs assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration until 7 days after administration. Serious adverse events occurring after 7 days after administration need only be reported if relationship to the investigational drug is suspected. The number of overall treatment emergent adverse events that occur will be reported for each cohort.

    Time frame: From Day 1 through study completion, up to 4 months

  2. Number of Dose-Limiting Toxicities (DLTs)

    A DLT for this protocol is defined as any event grade 3 or higher in severity assessed by the NCI CTCAE version 4.0 that is possibly, probably, or definitely attributable to the investigational drug, excluding laboratory abnormalities determined to be clinically insignificant. The number of DLTs for each cohort will be reported.

    Time frame: From Day 1 through study completion, up to 4 months

  3. Mean Change in 13C Pyruvate-to-Lactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)

    The mean change in 13C kPL from baseline to the post-RT scan will be calculated for normal appearing brain and tumor(s) (lesions) for Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.

    Time frame: Up to 8 weeks

  4. Mean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)

    The mean changes in 13C lactate/pyruvate ratio from baseline to the post-RT scan will be compared in the normal appearing brain and tumor(s) (lesions) for participants in Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.

    Time frame: Up to week 8

07

Results

Posted Oct 27, 2026
Limitations and caveats
This study closed to further enrollment earlier than expected due to slow enrollment.

Participant flow

Enrollment- Baseline Scan
Participant flow — Enrollment- Baseline Scan
MilestoneCohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Started1511
Completed1311
Not completed200
Withdrew: Scan determined to be non-evaluable by investigators200
Follow-up Scan
Participant flow — Follow-up Scan
MilestoneCohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Started1301
Completed400
Not completed901
Withdrew: Withdrawal by subject600
Withdrew: Scan not obtained or determined to be non-evaluable by investigators301

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events (AEs)

Participants will be monitored for the occurrence of treatment-emergent AEs assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration until 7 days after administration. Serious adverse events occurring after 7 days after administration need only be reported if relationship to the investigational drug is suspected. The number of overall treatment emergent adverse events that occur will be reported for each cohort.

Time frame:
From Day 1 through study completion, up to 4 months
Reported as:
Number · treatment-emergent adverse events
Number of Treatment Emergent Adverse Events (AEs)
treatment-emergent adverse eventsCohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Number of Treatment Emergent Adverse Events (AEs)000
PrimaryNumber of Dose-Limiting Toxicities (DLTs)

A DLT for this protocol is defined as any event grade 3 or higher in severity assessed by the NCI CTCAE version 4.0 that is possibly, probably, or definitely attributable to the investigational drug, excluding laboratory abnormalities determined to be clinically insignificant. The number of DLTs for each cohort will be reported.

Time frame:
From Day 1 through study completion, up to 4 months
Reported as:
Number · dose-limiting toxicities
Number of Dose-Limiting Toxicities (DLTs)
dose-limiting toxicitiesCohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Number of Dose-Limiting Toxicities (DLTs)000
PrimaryMean Change in 13C Pyruvate-to-Lactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)

The mean change in 13C kPL from baseline to the post-RT scan will be calculated for normal appearing brain and tumor(s) (lesions) for Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.

Time frame:
Up to 8 weeks
Reported as:
Mean · 1/seconds
Mean Change in 13C Pyruvate-to-Lactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)
1/secondsCohort 1: Newly Diagnosed GlioblastomaCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Lesion-24.1 (-61.8 to 1.6)—
Normal appearing brain1.9 (-4 to 10.9)—
PrimaryMean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)

The mean changes in 13C lactate/pyruvate ratio from baseline to the post-RT scan will be compared in the normal appearing brain and tumor(s) (lesions) for participants in Cohorts 1 and 3. Cohort 2 was not assigned to receive a second scan for comparison.

Time frame:
Up to week 8
Reported as:
Mean · change in lactate/pyruvate ratio
Mean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)
change in lactate/pyruvate ratioCohort 1: Newly Diagnosed GlioblastomaCohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Lesion-38.6 (-78.2 to -10.2)—
Normal appearing brain-4.6 (-19.9 to 8.5)—

Adverse events

Collected over Up to 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Newly Diagnosed Glioblastoma1/15 (6.7%)0/15 (0%)0/15 (0%)
Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection0/1 (0%)0/1 (0%)0/1 (0%)
Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

All enrolled participants will be included in safety analysis.

Age, Customized
Age, Customized(Participants)Cohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational TreatmentTotal
20-29 years old1NANANA
30-39 years old0NANANA
40-49 years old2NANANA
50-59 years old6NANANA
60-69 years old5NANANA
70-79 years old1NANANA
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational TreatmentTotal
Female4NANANA
Male11NANANA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational TreatmentTotal
American Indian or Alaska Native0NANANA
Asian1NANANA
Native Hawaiian or Other Pacific Islander0NANANA
Black or African American0NANANA
White14NANANA
More than one race0NANANA
Unknown or Not Reported0NANANA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational TreatmentTotal
Hispanic or Latino1NANANA
Not Hispanic or Latino14NANANA
Unknown or Not Reported0NANANA
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Newly Diagnosed GlioblastomaCohort 2: Recurrent Glioblastoma - Non-Investigational Surgical ResectionCohort 3: Recurrent Glioblastoma - Non-Investigational TreatmentTotal
United States151117
08

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Sep 2025, 70 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 15, 2019
StartActual
Nov 19, 2019
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Slow Accrual
changed Oct 27, 2026
Results
Results posted
posted Oct 27, 2026
Interventions
Added Drug: Hyperpolarized Pyruvate (13C)·Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI); removed Drug: Hyperpolarized 13C Pyruvate. Arm changed Cohort 1: Newly Diagnosed- Standard Treatment→Cohort 1: Newly Diagnosed Glioblastoma; Cohort 2: Recurrent- Standard Surgical Resection→Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection; Cohort 3: Recurrent- Standard Treatment→Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
Oct 27, 2026
Primary outcomes
3 edited, 1 added, 9 removed
What changed in the outcomes
  • EditedNumber of Dose-Limiting Toxicities (DLTs) Assessed by CTCAE Version 4.0Time frame: From Day 1 through study completion, up to 4 months
  • EditedDescribe ChangesMean Change in 13C pyruvatePyruvate-to-lactate conversion rateLactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)Time frame: Day 1 and Week 8 → Up to 8 weeks
  • EditedDescribeMean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)Time frame: Day 1 and Week 8 → Up to week 8
  • AddedNumber of Treatment Emergent Adverse Events (AEs)Time frame: From Day 1 through study completion, up to 4 months
  • RemovedNumber of Treatment Emergent Adverse Events (AEs) Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0Time frame: From Day 1 through study completion, up to 4 months
  • RemovedCompare 13C kPL Between Recurrent Lesions and Regions of Treatment Related EffectsTime frame: Day 1, Week 1-2, and Week 6-8
  • RemovedCompare 13C Lactate/Pyruvate Ratio Between Recurrent Lesions and Regions of Treatment Related EffectsTime frame: Day 1, Week 1-2, and Week 6-8
  • RemovedDetermine the Association Between 13C kPL and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
  • RemovedDetermine the Association Between 13C Lactate/Pyruvate Ratio and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
  • RemovedDetermine the Association Between Hydrogen-1 (1H) Choline-to-N-acetylaspartate (NAA) index (CNI) and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
  • RemovedDetermine the Association Between 13C kPL and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
  • RemovedDetermine the Association Between 13C Lactate/Pyruvate Ratio and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
  • RemovedDetermine the Association Between 1H CNI and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
Oct 27, 2026
Documents
Show all 1 update
  1. Oct 27, 2026
    Completed→Terminated
    Why stopped Slow Accrual
    Results posted
    Primary outcomes 3 edited, 1 added, 9 removed
    What changed in the outcomes
    • EditedNumber of Dose-Limiting Toxicities (DLTs) Assessed by CTCAE Version 4.0Time frame: From Day 1 through study completion, up to 4 months
    • EditedDescribe ChangesMean Change in 13C pyruvatePyruvate-to-lactate conversion rateLactate Conversion Rate (kPL) in Normal and Diseased Brain Tissues (Cohorts 1 and 3 ONLY)Time frame: Day 1 and Week 8 → Up to 8 weeks
    • EditedDescribeMean Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues (Cohort 1 and 3 ONLY)Time frame: Day 1 and Week 8 → Up to week 8
    • AddedNumber of Treatment Emergent Adverse Events (AEs)Time frame: From Day 1 through study completion, up to 4 months
    • RemovedNumber of Treatment Emergent Adverse Events (AEs) Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0Time frame: From Day 1 through study completion, up to 4 months
    • RemovedCompare 13C kPL Between Recurrent Lesions and Regions of Treatment Related EffectsTime frame: Day 1, Week 1-2, and Week 6-8
    • RemovedCompare 13C Lactate/Pyruvate Ratio Between Recurrent Lesions and Regions of Treatment Related EffectsTime frame: Day 1, Week 1-2, and Week 6-8
    • RemovedDetermine the Association Between 13C kPL and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
    • RemovedDetermine the Association Between 13C Lactate/Pyruvate Ratio and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
    • RemovedDetermine the Association Between Hydrogen-1 (1H) Choline-to-N-acetylaspartate (NAA) index (CNI) and Time to Disease ProgressionTime frame: From Day 1 until the date of documented disease progression, an average of 1 year
    • RemovedDetermine the Association Between 13C kPL and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
    • RemovedDetermine the Association Between 13C Lactate/Pyruvate Ratio and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
    • RemovedDetermine the Association Between 1H CNI and Overall SurvivalTime frame: From Day 1 until the date of death from any cause, up to 2 years
    Interventions Added Drug: Hyperpolarized Pyruvate (13C)·Procedure: Magnetic Resonance Spectroscopic Imaging (MRSI); removed Drug: Hyperpolarized 13C Pyruvate. Arm changed Cohort 1: Newly Diagnosed- Standard Treatment→Cohort 1: Newly Diagnosed Glioblastoma; Cohort 2: Recurrent- Standard Surgical Resection→Cohort 2: Recurrent Glioblastoma - Non-Investigational Surgical Resection; Cohort 3: Recurrent- Standard Treatment→Cohort 3: Recurrent Glioblastoma - Non-Investigational Treatment
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04019002
Lead sponsor
Susan Chang
Responsible party
Susan Chang (Professor, University of California, San Francisco) — Sponsor-investigator
First posted
Jul 15, 2019
Start date
Nov 19, 2019
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Susan Chang, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyperpolarized Carbon C 13 (1-13C) Pyruvate

Start the discussion